Login / Signup

Diabetes is a significant and independent predictor for tacrolimus immediate release and LCP-tacrolimus conversion ratios.

Kelsey CoffmanNeha PatelFelicia BartlettJessica NewmanShikha PatelTaylor SpragueNikhil RaoErika AndradeMichael J CaseyVinayak RohanDerek DuBayDavid J Taber
Published in: Clinical transplantation (2023)
Diabetes (DM) is a common comorbidity in transplant patients with known effects on gastrointestinal (GI) motility and absorption; however, DM's impact on immediate release (IR) tacrolimus to LCP-tacrolimus (LCP) conversion ratios has not been studied. This multivariable analysis of a retrospective longitudinal cohort study included kidney transplant recipients converted from IR to LCP between 2019 and 2020. The primary outcome was IR to LCP conversion ratio based on DM status. Other outcomes included tacrolimus variability, rejection, graft loss, and death. Of the 292 patients included, 172 patients had DM and 120 did not. The IR:LCP conversion ratio was significantly higher with DM (67.5% ± 21.1% no DM vs. 79.8% ± 28.7% in DM; P<0.001). In multivariable modeling, DM was the only variable significantly and independently associated with IR:LCP conversion ratios. No difference was observed in rejection rates. Graft (97.5% no DM vs. 92.4% in DM; P = 0.062) and patient survival (100% no DM vs. 94.8% in DM; P = 0.011) were lower with DM. The presence of DM significantly increased the IR:LCP conversion ratio by 13 to 14%, compared to patients without DM. On multivariable analysis, DM was the only significant predictor of conversion ratios, potentially related to GI motility or absorption differences. This article is protected by copyright. All rights reserved.
Keyphrases